FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 06:31:28 2024-06-28 EDT | ||
| 3.99 EUR / 4 EUR | +1.14% |
|
| Current month | -31.06% | ||
| 1 month | -31.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 3.98 | +0.76% |
| 24-06-27 | 3.95 | +3.95% |
| 24-06-26 | 3.8 | +9.51% |
| 24-06-25 | 3.47 | -18.35% |
| 24-06-24 | 4.25 | +0.47% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 06:27 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9KYG |
| ISIN | DE000SU9KYG0 |
| Date issued | 2024-02-20 |
| Strike | 858.3 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.89 € |
|---|---|
| Lowest since issue | 3.47 € |
| Spread | 0.01 € |
| Spread % | 0.25% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.28%
- Stock Market
- Certificates
- Certificat
